AGF Investments Inc’s United Therapeutics UTHR Stock Holding History

AGF Investments Inc’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,870	Closed	-$404K	–	702
2021 Q4	$404K	Buy	1,870 +1,070	+134%	+$210K	﹤0.01%	497
2021 Q3	$148K	Sell	800 -170	-18%	-$33.5K	﹤0.01%	661
2021 Q2	$174K	Sell	970 -146	-13%	-$27.8K	﹤0.01%	653
2021 Q1	$187K	Sell	1,116 -268	-19%	-$44.7K	﹤0.01%	619
2020 Q4	$210K	Sell	1,384 -2,078	-60%	-$273K	﹤0.01%	574
2020 Q3	$350K	Buy	3,462 +835	+32%	+$91.6K	﹤0.01%	518
2020 Q2	$318K	Sell	2,627 -124	-5%	-$14K	﹤0.01%	500
2020 Q1	$261K	Buy	+2,751	New	+$261K	﹤0.01%	495
2016 Q3	–	Sell	-366	Closed	-$39K	–	482
2016 Q2	$39K	Buy	+366	New	+$40.8K	﹤0.01%	388

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

AGF Investments Inc's UTHR Position: Q1 2022 in Review

AGF Investments Inc sold out of United Therapeutics (UTHR) in Q1 2022, closing a stake of 1,870 shares — an estimated $404K sold.

AGF Investments Inc first reported a position in UTHR in Q2 2016 and held it in 9 quarters. The position peaked at $404K in Q4 2021. 428 funds tracked by Wall St. Rank hold UTHR as of Q1 2022.

AGF Investments Inc reported no remaining United Therapeutics position as of Q1 2022 after selling out during the quarter.
AGF Investments Inc sold 1,870 United Therapeutics shares in Q1 2022, an estimated $404K.
AGF Investments Inc first reported a position in United Therapeutics in Q2 2016 and held it in 9 quarters.
AGF Investments Inc's United Therapeutics position peaked at $404K in Q4 2021.
428 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2022.

Based on AGF Investments Inc's 13F filing for Q1 2022, filed 10 May 2022.